SCHEMBL5035304

SCHEMBL5035304

CCN(CC)C(=O)c1csc(N(C(=O)c2ccc(Cl)cc2Cl)c2ccc(Cl)cc2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.54
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ALPL P05186 1/20 0.39
MAPK1 P28482 1/20 0.38
GFER P55789 1/20 0.38
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5035876 0.94 CYP3A4 (0.50) CYP3A4ALDH1A1MAPTL3MBTL1GABRA2
SCHEMBL5486463 0.93 CYP3A4 (0.49) CYP3A4ALDH1A1MAPTL3MBTL1GABRA2
SCHEMBL14190174 0.92 CYP3A4 (0.48) CYP3A4ALDH1A1MAPTL3MBTL1GABRA2
SCHEMBL5032541 0.92 CYP3A4 (0.52) CYP3A4ALDH1A1MAPTL3MBTL1GABRA2
SCHEMBL5032626 0.91 CYP3A4 (0.47) CYP3A4ALDH1A1MAPTL3MBTL1GABRA2
SCHEMBL5034860 0.89 CYP3A4 (0.47) CYP3A4ALDH1A1MAPTSMN1; SMN2CNR1
SCHEMBL5034722 0.88 CYP3A4 (0.44) CYP3A4ALDH1A1MAPTL3MBTL1GABRA2
SCHEMBL5034751 0.88 CYP3A4 (0.47) CYP3A4ALDH1A1L3MBTL1GABRA2GABRB2
SCHEMBL14190164 0.88 CYP3A4 (0.45) CYP3A4ALDH1A1MAPTGABRA2GABRB2
SCHEMBL5032585 0.87 CYP3A4 (0.44) CYP3A4ALDH1A1GABRA2GABRB2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US claimed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP claimed
JP-2007513193-A 2007-05-24 JP claimed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP claimed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US claimed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO claimed
US-9575957-B2 Recognizing chemical names in a chinese document INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2017-02-21 US disclosed
US-20130054226-A1 RECOGNIZING CHEMICAL NAMES IN A CHINESE DOCUMENT INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2013-02-28 US disclosed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 CYP3A4 693/4885ALDH1A1 473/4885MAPT 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.